Three years' experience with levonorgestrel-releasing intrauterine device and Norplant-2 implants: a randomized comparative study

A randomized comparative study of levonorgestrel-releasing intrauterine device (LNG-IUD) and Norplant^R-2 implants was carried out in 200 women for 36 months. Three thousand one hundred woman-months of use were observed with each device. Only one pregnancy occurred in users of LNG-IUD at the 12th month of use. The change in bleeding pattern was the most frequent reason for discontinuation. The discontinuation rate for irregular bleeding with Norplant-2 was 17.3 and 26.8 at 24 and 36 months, respectively, as compared to 3.3 with LNG-IUD at both 24 and 36 months. The differences were statistically significant. Removal for amenorrhea and pain only occurred in acceptors of LNG-IUD. About 20–40% of women using Norplant-2 had prolonged bleeding through 36 months. The percentage of amenorrhea in LNG-IUD was the highest (29.3%) at the end of two years of use. More than 97% of subjects reported satisfaction with the methods used by themselves.

---

Resumen Un estudio aleatorizado en el que se comparan los dispositivos intrauterinos que descargan levonorgestrel (LNG-IUD) con los implantes Norplant-2 se realizó en 200 mujeres durante 36 meses. Se observó un período de utilización correspondiente a tres mil cien meses-mujer con cada uno de los dispositivos. Hubo un solo embarazo, en el decimosegundo mes, entre las usuarias de LNG-IUD. La alteración del flujo menstrual fue la razón invocada con mayor frecuencia para el abandono del método. Los porcentajes de abandono por la irregularidad de la menstruación en el caso de los Norplant-2 fue de 17,3 y 26,8 a los 24 y 36 meses, respectivamente, en comparación con 3,3 con los LNG-IUD a los 24 y 36 meses. Estas diferencias son estadísticamente significativas. El retiro por amenorrea y dolores sólo ocurrió entre las mujeres que tenían los LNG-IUD. Los Norplant-2 ocasionaron sangrado prolongado durante los 36 meses estudiados en alrededor del 20 al 40% de las mujeres. El porcentaje de amenorrea con los LNG-IUD llegó al nivel máximo (29,3%) al cabo de dos años de uso. Más del 97% de las mujeres se mostraron satisfechas con los métodos que utilizaban.

---

Resumé Une étude randomisée comparant les dispositifs intra-utûrins libérant du lévonorgestrel (LNG-IUD) aux implants Norplant-2 a été effectuée sur 200 femmes pendant 36 mois. On a ainsi observé une période d'utilisation correspondant à trois mille cent mois/femme avec chacun des dispositifs. Une seule grossesse s'est produite, au douzième mois, parmi les utilisatrices de LNG-IUD. L'altération du flux menstruel a été la raison le plus souvent invoquée pour l'abandon de la méthode. Les pourcentages d'abandon du fait de l'irrégularité de la menstruation dans le cas des implants se sont élevés à 17,3 et 26,8 après respectivement 24 et 36 mois, alors qu'ils n'atteignaient que 3,3 pour les LNG-IUD, tant à 24 qu'à 36 mois. Ces différences sont statistiquement significatives. Le retrait à la suite d'aménorrhée et de douleurs n'a été constaté que chez des femmes portant les LNG-IUD. Le Norplant-2 a occasionné des saignements prolongés pendant les 36 mois étudiés chez environ 20 à 40% des femmes. Dans le cas des LNG-IUD, le taux d'aménorrhée était le plus élevé (29,3%) au terme de deux années d'utilisation. Plus de 97% des patientes se sont dites satisfaites de la méthode qu'elles appliquaient.

     

胰激肽原酶治疗糖尿病足38例疗效分析

目的 观察胰激肽原酶改善微循环干预治疗糖尿病足的疗效。方法 选择38例确诊为糖尿病足的患者，结合下肢血管多普勒超声显像、肌电图、血液流变学检测，确定疗效。结果 胰激肽原酶治疗后，肢体影色多普勒超声显像显示下肢血管血流明显加快(P＜0．01)；神经电生理异常均有不同程度改善；血液粘度明显下降(P＜0．01)；足部症状明显缓解。结论 胰激肽原酶是一种干预糖尿病足进展的有效药物。     

Histological Changes and Differential Diagnosis of Mesenchymal Chondrosarcoma

Eight cases of mesenchymal chondrosarcoma either of skeletal(5 cases) or extrasketetalorigin (3 cases) are reported. According to histopathological and diagnostic criteria,mesenchymal chondrosarcoma were classified into two types cartilage isiand cell type andundifierentiated small cell type It is believed that the application of this classification in the study ofmesenchymal chondrosarcoma is helptul the estimation of its malignancy and choice of treatmentas well al in the prediction of its prognosis. Mesenchymal chondrosarcoma is a highly malignant neoplasm with poor prognosis. None ofthe patients in this series survived more than five years after they were diagnosed. The diffentialdiagnosis of malignant lymphoma, chondrosarcoma, hemangiopericytosarcoma, etc. was discussed.My data support the assumption that mesenchymal chondrosarcoma originates from the secondarymesenchyme rather than the primary mesenchyme.     

人胎儿前庭器超微结构的观察

对人胎儿前庭器超微结构的研究,国内外报道甚少。本文对18至36周人胎儿颞骨10具进行了扫描电镜和透射电镜的观察,并对应用Surface preparation法制做人胎儿前庭器标本的方法进行了探讨。本文观察所见:豚鼠平衡斑的生理状态与人胎儿很近似,体面积比人胎儿平衡斑小,感觉毛长,细胞排列更整齐。28周以后的胎儿因前庭周围骨质变硬,制做标本时可以分别取出两囊斑和壶腹嵴。     

TOCP染毒母鸡的神经电生理研究

对TOCP染毒母鸡进行为期7周的神经电生理监测,结果表明,TOCP主要影响远端周围神经,导致坐骨神经远端MCV和SCV减慢及腓肠肌EMG失神经样改变,而胫后神经H反射及重复电刺激无明显异常。     

急性梗阻性化脓性胆管炎(附121例分析)

本文对121例急性梗阻性化脓性胆管炎(AOSC)进行了临床分析讨论了诊断及治疗。结果表明,早期诊断,尽快手术治疗,积极防治并发症,是提高疗效降低死亡的关键。肝肾功能衰竭和中毒性休克是本病的主要死因,占死亡总人数的83％,60岁以上的老人不是手术的禁忌症。     

全国细菌药敏试验的室间质量评价

目的：了解全国大中型医院细菌药敏试验（AST）状况，提高检测水平和质量。方法：定期向全国各参加评价实验室发放冻干标本，要求在规定时间内报告可疑感染的病原菌及其药敏结果，对回报结果给予数据统计、分析和评价。结果：2000年全国489个细菌室对常见耐药菌的检测正确率分别为：超广谱β－内酰胺酶63％（ESBLs)；苯唑西林敏感金黄色葡萄球菌（MSSA）74％；苯唑西林耐药凝固酶阴性葡萄球菌（MRSCoN)48％；对青霉素不敏感肺炎链球菌7％；氨基糖苷类高水平耐药肠球菌95％；产β－内酰胺酶流感嗜血杆菌正确率35％。结论：通过细菌药敏试验的室间质量评价反映出我国的细菌耐药性检测水平急待提高。     

32例出血性梗塞研究分析

对32例出血性梗塞研究分析，发现常出现于脑栓塞及大面积脑血栓病人。以治疗中病情突然加重或持久症状不改善为特征，动态CT检查对本病的诊断及治疗有重要意义。     

N-methyl-D-aspartate exposure blocks glutamate toxicity in cultured cerebellar granule cells.

Exposure of cultured cerebellar granule cells to glutamate results in a concentration-dependent (EC50 = 22.7 +/- 0.4 microM) and delayed (24-72 hr) neurotoxicity, which is blocked by the specific N-methyl-D-aspartate (NMDA) receptor antagonists 2-amino-5-phosphovalerate and MK-801 but is unaffected by the non-NMDA receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione and 6,7-dinitroquinoxaline-2,3-dione. Although glutamate toxicity in these cells is mediated by the NMDA subtype of glutamate receptor, pretreatment of cerebellar granule cells with subtoxic concentrations of NMDA markedly antagonizes the neurotoxic actions of glutamate, with an IC50 of 55 +/- 4 microM. The neuroprotective effect of NMDA requires a preincubation time of approximately 120 min to be fully manifested and does not require the presence of NMDA during glutamate exposure. These data demonstrate that NMDA receptors mediate both neurotoxicity and neuroprotection in cerebellar granule cells. Among four glutamate receptor agonists tested (NMDA, quisqualate, ibotenate, and kainate), only NMDA was able to provide a robust neuroprotection against glutamate toxicity. Quisqualate was neither neurotoxic nor neuroprotective, whereas ibotenate, which was nontoxic by itself, induced a small degree of neuroprotection. In contrast, kainate, which was neurotoxic to cerebellar granule cells, also provided considerable neuroprotection against glutamate toxicity. Because preincubation of cerebellar granule cells with NMDA fails to alter NMDA receptor-mediated phosphoinositide hydrolysis or the specific binding of [3H]MK-801 to NMDA receptors, it appears that the neuroprotective effects of NMDA are not due to NMDA receptor desensitization.     

Comparative Study on the Immunogenicity between Recombinant MS-Sj26GST Vaccine and Recombinant BCG-Sj26GST Vaccine in Schistosoma japonicum

TuberculosisandSchistosomiasisarethemajorcontagiousdiseaseswhicharethemostdangeroustothepeople’shealth Inordertogetridofthem ,wemustlookforamoreusefulvaccine Bythetech niquesofmolecularbiology ,2 6 0 0 0DaGlutathionStransferase (GST) genewasclonedintotheE coli MycobacteriumtransferringandexpressionvectorpBCG 2 0 0 0totransformittoMycobacteriumsmeg matismc2 15 5 (MS)andBCGseparatelyinordertoconstructrMS Sj2 6GSTvaccineandrBCG Sj2 6GSTvaccine Inthisstudy ,theBALB/cmicewereimmu niz…